Company Insulet Corporation

Equities

PODD

US45784P1012

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
171.7 USD +3.51% Intraday chart for Insulet Corporation -5.22% -20.88%

Business Summary

Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows:

- Insulin pump therapy systems (95.6%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand);

- non-insulin drug administration systems (4.4%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy).

By the end of 2022, the group will have 2 production sites located in the United States and in China.

The United States accounts for 72.2% of net sales.

Number of employees: 3,000

Sales per Business

USD in Million2022Weight2023Weight Delta
United States Omnipod
73.7 %
885 67.8 % 1,251 73.7 % +41.39%
International Omnipod
24.2 %
363 27.8 % 410 24.2 % +12.98%
Drug Delivery
2.1 %
58 4.4 % 36 2.1 % -37.39%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
75.8 %
942 72.2 % 1,287 75.8 % +36.58%
International
24.2 %
363 27.8 % 410 24.2 % +12.98%

Managers

Managers TitleAgeSince
Chief Executive Officer 61 19-07-30
Founder 54 13-12-31
Director of Finance/CFO 49 19-04-28
Chief Tech/Sci/R&D Officer - 18-12-31
Chief Operating Officer 47 -
Chief Tech/Sci/R&D Officer - 16-09-11
Director/Board Member 51 15-02-09
Corporate Officer/Principal - -
Human Resources Officer 57 20-04-30
Corporate Officer/Principal 41 18-01-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 57 17-08-09
Chairman 60 14-08-13
Director/Board Member 64 22-02-03
Director/Board Member 64 19-01-27
Chief Executive Officer 61 19-07-30
Director/Board Member 52 20-10-19
Director/Board Member 51 15-02-09
Director/Board Member 59 15-07-26
Director/Board Member 53 21-10-17
Director/Board Member 51 Jan. 17

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 69,925,730 69,532,792 ( 99.44 %) 0 99.44 %

Shareholders

NameEquities%Valuation
Capital Research & Management Co. (Global Investors)
13.55 %
9,476,623 13.55 % 1 554 M $
Vanguard Fiduciary Trust Co.
11.48 %
8,029,608 11.48 % 1 317 M $
Fidelity Management & Research Co. LLC
8.400 %
5,873,837 8.400 % 963 M $
BlackRock Advisors LLC
6.907 %
4,829,431 6.907 % 792 M $
Wellington Management Co. LLP
4.642 %
3,246,124 4.642 % 532 M $
2,884,915 4.126 % 473 M $
Capital Research & Management Co. (World Investors)
3.163 %
2,211,778 3.163 % 363 M $
Geode Capital Management LLC
2.302 %
1,609,418 2.302 % 264 M $
Citadel Securities GP LLC
1.904 %
1,331,394 1.904 % 218 M $
ClearBridge Investments LLC
1.899 %
1,327,851 1.899 % 218 M $

Company contact information

Insulet Corp.

100 Nagog Park

01720, Acton

+978 600 7000

http://www.insulet.com
address Insulet Corporation(PODD)